newsfilter
← Latest News
Business Wire·

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

– ECLIPSE registrational program in chronic hepatitis delta fully underway – First patient dosed in Phase 1 study of VIR-5525, an EGFR-targeting PRO-XTEN™ dual-masked T-cell engager; advancing oncology clinical